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Background & Aims: The colonic epithelial cells near the
top of the crypt have been shown to undergo apoptosis.
Because butyric acid (BA) is the major short-chain fatty
acid produced by fermentation of dietary fiber in the
large bowel, it may be an important regulator of apo-
ptosis in colorectal cancer. We investigated which sig-
naling pathway is triggered by BA to undergo apoptosis
in human colorectal cancer cells. Methods: Human DiFi
and FET colorectal cells were treated with BA to undergo
apoptosis and were assayed for activation of c-Jun N-
terminal kinase (JNK), transcription factor activation
protein 1 (AP1) and NF-kB, and the proapoptotic mole-
cule Bax. The contribution of specific pathways was
assessed by examining the effects of dominant-negative
mutants of JNK/AP1 or NF-kB on BA-induced Bax ex-
pression and apoptosis. Results: BA-mediated DNA frag-
mentation and Bax induction were preceded by early
stimulation of JNK, and the DNA-binding activities of
AP1 and NF-kB. BA-induced enhancement of DNA frag-
mentation and stimulation of Bax promoter activity were
blocked by the expression of dominant-negative mu-
tants of JNK1 or AP1 but not NF-kB. Conclusions: These
findings suggest that apoptosis triggered by BA involves
transcriptional stimulation of the Bax gene via activation
of the JNK/AP1 pathway in colonic epithelial cells.
Several studies suggest that dietary factors are involvedin the control of colonic cell growth and differentia-
tion and, therefore, in the etiology of large-bowel can-
cer.1 High-fiber diets may protect against development
of colorectal cancer,2 in large part because of production
of short-chain fatty acids, particularly butyrate, by an-
aerobic fermentation of insoluble fiber in the colon.3
Studies using a rat model of colon cancer have demon-
strated that dietary supplementation of fiber leads to
increased colonic butyrate levels, reduced cell prolifera-
tion, and reduced tumor mass.4 Butyrate, the preferred
oxidative fuel of colonocytes, has a tropic effect on the
colonic mucus, and induces cell arrest and terminal dif-
ferentiation, influences gene expression, alters cell mor-
phology, and induces apoptosis in colon cancer cells
(reviewed by Smith et al.5). However, the mechanism for
its protective effects has not yet been established.
Because colonic epithelial cells near the apex of the
crypt can undergo apoptosis,6,7 and because butyric acid
(BA) is locally produced in the large bowel, one potential
mechanism for the protective effects of dietary fiber is
BA-induced apoptosis. Apoptosis plays an important role
in the maintenance of tissue homeostasis and also seems
to be important in the normal colon in vivo.6,8,9 Thus,
deregulation of apoptosis may be involved in the survival
and development of colorectal cancer.10 Recent studies
suggest that cells derived from a variety of human can-
cers, including colorectal cancer,10 have decreased apo-
ptosis in response to various physiologic stimuli.11,12 In
addition, colonic epithelial cells at the apex of crypts
display strong immunoreactivity to the proapoptotic
protein Bax.6 Bax forms homodimers and heterodimers
with antiapoptotic family members such as Bcl-2, Bcl-
XL, and McL1.13,14 Current model suggests that the ratio
of antiapoptotic to proapoptotic proteins plays a regula-
tory role in apoptosis.
Activation of the c-Jun N-terminal kinase (JNK), a
member of the mitogen-activated protein kinase family,
is involved in mediating apoptosis induced by a variety
of agents, including nerve growth factor withdrawal,
chemotherapeutic drugs, DNA-damaging agents, and
gamma irradiation.15–17 The activation of JNK involves
phosphorylation at Thr-183 and Tyr-185 by JNK kinase
(also known as MEKK1).18 Once activated, JNK induces
phosphorylation of c-Jun at Ser-63 and Ser-73, enabling
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c-Jun to induce transcription of genes containing a bind-
ing site for the activation protein 1 (AP1) complex,
which consists of dimers between members of the Jun
and fos families, including c-Jun itself.18 Overexpression
of JNK induces apoptosis, and expression of dominant-
negative mutants of the components of the JNK/AP1
pathway inhibit apoptosis induced by growth factor
withdrawal or cytotoxic agents,16 suggesting that stim-
ulation of the AP1 pathway is required for the activation
of downstream molecules, such as caspases, that orches-
trate apoptosis. Caspase inhibitors can block JNK and
p38 mitogen-activated protein kinase activation in re-
sponse to some agent(s), suggesting that these pathways
may be downstream of caspase activation.19 However,
overexpression of upstream regulator of JNK such as
MEKK1 can also induce caspase activity and apopto-
sis.19–21 Research suggests that the JNK pathway may
function both downstream and upstream of caspases in
the apoptotic response, depending on the cell type and
nature of the apoptotic signal.19–21 Furthermore, it has
been proposed that caspases work both upstream and
downstream of JNK and are involved in a positive-
feedback pathway that amplifies the apoptotic re-
sponse.21 The implication of apoptotic agent-induced
stimulation of signaling kinases is that it may lead to
activation of downstream transcription factors involved
in apoptosis, including c-Jun, c-fos, and NF-kB.22 Sim-
ilarly, a number of cytotoxic drugs have been shown to
activate NF-kB and induce apoptosis.17,23 Activated
caspases can also cleave IkB, an endogenous inhibitor of
NF-kB, to contribute activation of NF-kB.24
The molecular mechanism by which butyrate induces
apoptosis is not well established. Recent studies suggest
that butyrate-mediated apoptosis in colonic epithelial
cells involves activation of caspase-325 and requires
mitochondrial function.26 We now report that buty-
rate-mediated DNA fragmentation and Bax induction
characteristics of apoptosis were preceded by early stim-
ulation of JNK, AP1, and NF-kB. BA-induced enhance-
ment of DNA fragmentation and stimulation of Bax-
promoter activity were blocked by the expression of a
dominant-negative mutant of JNK1 or AP1, but not
NF-kB. These findings suggest that apoptosis triggered
by BA involves transcriptional stimulation of the Bax
gene via activation of the JNK/AP1 pathway in colonic
epithelial cells.
Materials and Methods
Cell Cultures and Extracts
Human DiFi and FET colorectal carcinoma cells were
maintained in Dulbecco’s modified Eagle medium–F12 (1:1)
supplemented with 10% fetal calf serum.27–29 Cells were lysed,
and lysates (30 mg protein) were resolved by 7% or 10%
sodium dodecyl sulfate (SDS)–polyacrylamide gel electro-
phoresis (PAGE), followed by transfer to the membranes and
probing with the desired antibodies, and immune complexes
were detected by using an enhanced chemiluminescent system.
All antibodies, including the anti-Bax Ab (N-20) were ob-
tained from Santa Cruz Biotechnology (Santa Cruz, CA). So-
dium butyrate was purchased from Sigma Chemical Co. (St.
Louis, MO).
Apoptotic Assays
For DNA fragmentation assay, low-molecular-weight
DNA was isolated as described previously.29,30 Briefly, cells
(3 3 106/plate) were seeded in 100-mm plates and treated
with or without BA. Both floating and attached cells were
scraped and collected in medium, washed 3 times with phos-
phate-buffered saline (PBS), and resuspended in 1 mL of lysis
buffer (20 mmol/L Tris-HCl [pH 8], 10 mmol/L EDTA [pH
8], and 0.5% Triton X-100). Low-molecular-weight DNA was
extracted from the supernatant and visualized by 1.5% agarose
gel electrophoresis and ethidium bromide staining.30 The per-
centages of cells in different phases of the cell cycle were
determined by staining with propidium iodide (Sigma) and
analyzing cells on a FACScan (Becton Dickinson, Franklin
Lakes, NJ) at 514 nm as described.30
JNK Assay
For the JNK assay, cell lysates containing 500 mg
protein were incubated with a glutathione S-transferase (GST)–
fusion protein containing N-terminal amino acids 1–89 of
c-Jun. JNK was precipitated with GST beads, and the in vitro
kinase assay was performed as described previously.31
Electrophoresis Mobility Shift Assay
Cells were washed with PBS and collected by centri-
fugation. Cytosolic and nuclear extracts were prepared. The
electrophoresis mobility shift assay (EMSA) was performed by
incubating the nuclear extract (5 mg) with a 32P-radiolabeled,
high-affinity, double-stranded AP1 oligonucleotide (Santa
Cruz Biotechnology). The DNA-protein complexes were re-
solved on native 5% polyacrylamide gels. For supershift assays,
1 mL of antibody against each of the AP1 subunits was added
to the EMSA reaction 10 minutes before electrophoresis.30
Metabolic Labeling
An equal number of cells were treated with or without
BA for 12 hours. Cells were metabolically labeled with 100
mCi/mL [35S]methionine in methionine-free medium contain-
ing 2% fetal bovine serum during the last 6 hours of incuba-
tion. Cells were then washed twice with PBS, and lysates were
prepared. Lysates containing equal amounts of perceptible
trichloroacetic acid counts were immunoprecipitated with the
desired monoclonal antibodies, resolved on an SDS–polyacryl-
amide gel, and analyzed by autoradiography.28
72 MANDAL ET AL. GASTROENTEROLOGY Vol. 120, No. 1
Luciferase Assays
Colonic cells were serum starved in low-serum me-
dium (Dulbecco’s modified Eagle medium containing 0.1%
serum) for 28 hours. Cells were then transiently cotransfected
with a luciferase plasmid and a control pSVb-Gal vector (Pro-
mega, Madison, WI) using Lipofectamine (GIBCO, Rockville,
MD). Luciferase activity was measured 36 hours after trans-
fection using a luciferase assay kit (Promega) as described.32
Cells were lysed in Reporter Assay Buffer (Promega). An
aliquot (20 mL) of the lysate was used to determine the
luciferase assay by means of a luciferase assay kit from Pro-
mega. Another aliquot (10 mL) of the same lysate was used to
determine b-galactosidase activity using the Galacto-light sys-
tem and luminometer. b-Galactosidase activity was used to
normalize transfection efficiencies. Where indicated, cells were
treated with 3 mmol/L BA before lysis.
Construction of a Mutated Bax Promoter
A 370–base pair (bp) Bax-luciferase construct encod-
ing the 2680 to 2317 region of the Bax promoter33,34 was
used to generate AP1 wild-type or mutated constructs by
polymerase chain reaction. The 370-bp PGL3-bax plasmid
was used as a template with the following oligonucleotides:
forward primer Ap1wt, 59-GCAAGGTACCAAACCACT-
CAGT-3, and Ap1wt, 5-TACGGTACCACCTCGTTTT-
TAGTCATC-39; and reverse primer: 59-CTTTATGTTTTT-
GGCGTCTTC-39. Amplified products were digested with
KpnI and XhoI enzymes and cloned into the PGL3 vector. To
verify the AP1 mutation, constructs were sequenced.
Results and Discussion
BA Induces Apoptosis in Human
Tumor Cells
We and other investigators have shown that BA
induces apoptosis in human colorectal carcinoma
cells.5,27–29 In the present study, we set out to delineate
the signaling pathway that leads to this induction of
apoptosis in response to BA. We show that treatment of
FET colorectal cancer cells with BA was accompanied by
induction of apoptosis in a time-dependent manner, as
determined by the appearance of DNA fragmentation
(Figure 1A ), enhancement in the percentage of cells in
the pre-G0 apoptotic population (Figure 1B), proteolytic
cleavage of lamin B1 and PARP (poly[ADP-ribose] poly-
merase), and activation of caspase-3 (Figure 1C ).
BA-Induced Apoptosis Is Accompanied
by Increased Expression of Bax
Because apoptosis is regulated by the ratio be-
tween proapoptotic and antiapoptotic gene products, and
because Bcl-2 overexpression leads to inhibition of BA-
induced apoptosis,27 we hypothesized that BA-regulated
apoptosis involves Bax and thus modulates the ratio of
Bax to Bcl-2 in favor of cell death. Therefore, we exam-
ined the effect of BA on Bax expression in colorectal
cancer cells. As shown in Figure 2A, treatment of FET
cells with BA stimulated Bax protein expression in a
time-dependent manner starting at 6 hours after treat-
ment. As an internal control, the upper portion of the
Bax blot was probed with an unrelated antibody against
vinculin. To examine FET cells for newly synthesized
Bax protein, we showed that BA treatment resulted in
increased expression of [35S]methionine-labeled Bax pro-
tein (Figure 2B) and Bax messenger RNA (Figure 2C ).
BA-Induced Apoptosis Is Accompanied by
Increased Stimulation of JNK Activity
To examine the role of the JNK pathway in
BA-induced apoptosis in colorectal cancer cells, we ex-
amined FET cells for JNK activity after treatment with
BA. Cells were treated with BA for various times, and
Figure 1. BA induces apopto-
sis in FET colon cancer cells.
(A) Cells were cultured with 3
mmol/L sodium butyrate for
different times, and DNA frag-
mentation was measured by
ethidium bromide staining.
(B) Fluorescence-activated cell
sorter profile of cells treated
with 3 mmol/L BA for 24 hours.
Bar shows apoptotic cells. (C)
Cells were treated with 3
mmol/L BA for different times,
and cell extracts were immuno-
blotted with the indicated anti-
bodies.
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JNK1 activity was measured in cell extracts by immu-
noprecipitation with a c-Jun–specific antibody and an
immunocomplex kinase assay using GST-Jun as a sub-
strate. As shown in Figure 3A, BA treatment induced
stimulation of JNK1 activity with a maximal activation
between 3 and 6 hours after treatment. BA has no effect
on ERK activity (data not shown). In brief, data to this
point suggested that the activation of JNK preceded the
appearance of DNA laddering in BA-treated cells.
BA Stimulates Activation of AP1
Recent studies suggest that the apoptosis-induc-
ing function of JNK is associated with JNK’s ability to
induce expression of the AP1 transcription factor.35
Therefore, we examined the effects of BA on activation of
DNA-binding activity of AP1 in FET cells using EMSA
with nuclear extracts. As shown in Figure 3B, BA treat-
ment resulted in a transient increase in AP1 DNA-
binding activity at 3 hours. The observed AP1-DNA
complex was competed by a 100-fold molar excess of
unlabeled AP1 probe and thus resulted from specific
DNA-protein interaction (data not shown). We next
determined which AP1 subunits were in the major AP1-
DNA complex. Antibody supershift experiments dem-
onstrated that incubation of nuclear extracts with a c-
Jun–specific (and not a c-fos–specific) antiserum resulted
in supershift of the AP1-DNA binding complex (Figure
3C ). To examine whether BA-induced AP1 activity
could stimulate the transcriptional activation of its target
genes in vivo, we used a reporter construct with a 137-bp
collagenase-gene promoter containing a single AP1 site
(TGAGTCA) fused with the luciferase gene. In this
assay, activation of luciferase transcription would indi-
cate functional Jun/Jun dimers binding to the AP1 con-
sensus sequence. As shown in Figure 3D, BA treatment
stimulated activation of AP1-driven transcription in FET
cells. Together, these results established that BA stimu-
lation of JNK1 was accompanied by activation of the
AP1 transcription factor.
Studies have shown that NF-kB can also modulate
apoptosis17,23; we next explored whether BA could in-
duce NF-kB in colorectal cancer cells. As shown in
Figure 3D, BA stimulated the DNA-binding activity of
NF-kB in FET cells.
BA-Triggered Apoptosis Requires
a Functional AP1 Pathway
To assess the involvement of AP1 activation dur-
ing BA-induced apoptosis, we examined the effects of
transient expression of dominant-negative c-Jun mutant
TAM 67 (lacking its transactivation domain) or TAM-fos
(leucine-zipper domain of TAM 67 replaced with leucine
zipper of c-fos so that it can heterodimerize only with
Jun family members)36 or a dominant-negative JNK1
mutant on BA-induced AP1 activation, DNA fragmen-
tation, and lamin B1 cleavage. Expression of TAM67 or
JNK1 mutants in FET cells significantly inhibited BA-
triggered stimulation of AP1 DNA-binding activity
(Figure 4A ), DNA fragmentation (Figure 4B), and gen-
eration of lamin B1 fragments (Figure 4C ). Quantitation
of cell viability indicated that dominant-negative JNK1
mutants reduced the percentage of dead cells in BA-
treated FET cells (Figure 4D). Although BA stimulated
the DNA-binding activity of NF-kB (Figure 3D), BA-
mediated DNA fragmentation remained unaffected by
expression of an IkB-S12 mutant (Figure 4E ) that effec-
tively blocks stimulation of NF-kB activity.37 Similar
results were obtained with DiFi cells. Because BA-in-
duced apoptosis was blocked by dominant-negative mu-
tant of JNK1 but not by NF-kB, these results suggested
that BA-induced apoptosis may involve stimulation of
Figure 2. BA induces expression of Bax. (A) FET cells were treated
with 3 mmol/L BA for indicated times. Cell extracts were analyzed by
SDS-PAGE and immunoblotted with an anti-Bax antibody (upper
panel). As an internal control, the upper portion of the Bax blot was
blotted with an unrelated antivinculin antibody (lower panel). (B) Cells
were treated with or without 3 mmol/L BA for indicated times and
metabolically labeled with [35S]methionine for the final 3 hours. Ly-
sates containing equal amounts of perceptible trichloroacetic acid
counts (cpm) were immunoprecipitated with an anti-Bax antibody and
analyzed by SDS-PAGE. (C) FET cells were treated without (lane 1) or
with 3 mmol/L BA for 3 hours (lane 2) or 6 hours (lane 3). One
hundred nanograms of RNA from each condition was analyzed by
reverse-transcription polymerase chain reaction for the expression of
Bax or glyceraldehyde-3-phosphate-dehydrogenase messenger RNA.
Results shown are representative of 3 independent experiments.
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AP1 DNA-binding activity and not NF-kB DNA-bind-
ing activity.
BA Up-regulates Bax Promoter Activity
via the JNK Pathway
Next, we hypothesized that BA-mediated Bax
expression involves AP1. To examine whether BA could
stimulate the transcription of Bax in vivo, we used a
reporter construct in which a 972-bp Bax promoter33,34
containing several AP1 sites was fused with the luciferase
gene. As shown in Figure 5A, BA treatment stimulated
the activation of Bax transcription in FET cells. This
activity was suppressed in FET and DiFi cells by the
expression of dominant-negative JNK1 or TAM67 mu-
tants (Figure 5B and C ).
To further define the role of AP1 sites in BA-mediated
Bax transcription, we examined a series of Bax-promoter
deletions to identify the region responsive to BA. BA
treatment resulted in a 4-fold increase in induction from
a 370-bp construct encoding the 2680 to 2317 region
of the Bax promoter,33,34 suggesting the presence of the
BA-responsive element. Analysis of this sequence in the
Transcription Factor Database V1.338 revealed the pres-
ence of an AP1 site in the 2416 to 2410 region. To
evaluate the contribution of this AP1 site to the regula-
tion of Bax-promoter activity by BA, we constructed 2
luciferase constructs containing the 2420 to 317 region
of the promoter, either wild-type (AP1wt; ACTCAGT)
or mutated (AP1mt; ACCTCGT), in the AP1 site. Treat-
ment with BA caused a 4-fold stimulation of luciferase
activity from the AP1wt construct. However, mutation
of the AP1 site reduced the stimulation in luciferase
Figure 3. BA-induced apoptosis is accompanied by stimulation of the JNK/AP1 pathway. (A) FET cells were treated with or without 3 mmol/L BA
for different times, and cell extracts were assayed for JNK activity, using GST-Jun as a substrate. The kinase reaction products were resolved
on a 10% SDS-polyacrylamide gel, transferred to a nitrocellulose membrane, and visualized by phosphoimaging. (B) FET cells were treated with
or without 3 mmol/L BA, and nuclear extracts were assayed for AP1 DNA-binding activity. Arrowhead shows AP1-DNA complex. (C) Nuclear
extracts from control and BA-treated FET cells were incubated with a c-Jun–specific or c-fos–specific antiserum. Top 2 arrowheads show supershift
of the AP1-DNA. (D) FET cells were transiently transfected with a reporter gene construct containing an AP1 site, treated with or without 3 mmol/L
BA for 24 hours, and measured for luciferase activity. (E) FET cells were treated with or without 3 mmol/L BA, and nuclear extracts were assayed
for NF-kB DNA binding activity. Similar results were obtained in 3 or more independent experiments.
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activity to 1.5-fold. These results suggested a potential
role of the AP1 site located in the 2416 to 2410 region
of the Bax promoter in the promoter’s BA-mediated
stimulation. These results suggested that BA-induced
apoptosis involved stimulation of AP1 DNA-binding
activity.
This study demonstrates that treatment with BA can
activate a signaling pathway that includes the stimula-
tion of JNK1 and AP1, and may be involved in apoptotic
cell death of colorectal cancer cells. It is well accepted
that JNK is the only enzyme that can phosphorylate
c-Jun at Ser-63 and Ser-73, and induce the transcription
of genes containing AP1 consensus sites.22 On the other
hand, phosphorylation of the carboxyl domain of c-Jun
by ERK has been shown to inhibit its DNA-binding
function.37 In this context, our observation that BA
induced AP1 DNA-binding activity without any influ-
ence on ERK is consistent with the involvement of JNK
in activating AP1. Furthermore, we demonstrated an
essential role for the JNK/AP1 pathway in BA-induced
apoptosis (by directly blocking the JNK1 function). In
addition, we demonstrated that BA-stimulated AP1 ac-
Figure 4. BA-induced apoptosis requires the JNK/AP1 pathway. (A) FET cells were transiently transfected with dominant-negative JNK1 (lanes
3 and 4) or TAM 67 (lanes 5 and 6) mutants and treated with or without 3 mmol/L BA for 3 hours. Nuclear extracts were assayed for AP1
DNA-binding activity. Arrowhead shows AP1-DNA complex. (B) FET cells were transiently transfected with dominant-negative JNK1 (lanes 3 and
4), or TAM 67 (lanes 5 and 6), or TAM/Fos (lanes 7 and 8) mutants and treated with or without 3 mmol/L BA for 20 hours. DNA fragmentation
was measured by ethidium bromide staining. (C) Cell lysates from duplicate culture plates from the panel B experiment were analyzed by
SDS-PAGE and immunoblotted with an anti–lamin B1 monoclonal antibody. (D) FET cells were transfected with dominant-negative JNK1 and
treated with or without 3 nmol/L BA for 20 hours. Cellular viability was determined by trypan blue staining. Results are representative of 2
separate experiments. (E) FET cells were transiently transfected with a caspase-3 inhibitor (lanes 1 and 2) or a dominant-negative IkB mutant
(lanes 3 and 4) and treated with or without 3 mmol/L BA for 20 hours. DNA fragmentation was measured by ethidium bromide staining. Results
are representative of 3 experiments.
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tivity may regulate the transcription of the proapoptotic
gene Bax, whose promoter contains an AP1 consensus
sequence. Our findings raise questions about the intra-
cellular events that result from BA treatment and lead to
stimulation of JNK1 activity. It is possible that inhibi-
tion or activation of certain signal-transduction pathways
modulated by BA alters the status of different proteins
that can activate JNK. Alternatively, BA treatment may
alter the intracellular pH and activate JNK. Because BA
is a very potent activator of a number of cellular genes,
we cannot rule out the potential role of BA in up-
regulating signal-transduction components that regulate
JNK activity. The possible role of upstream regulators of
JNK activation and the manner in which these putative
regulators are activated by BA remain to be explored. In
summary, we provide evidence to suggest that activation
of the JNK/AP1 pathway, and not the NF-kB pathway,
regulates short-chain fatty acid–induced apoptosis, pos-
sibly by up-regulating the expression of the proapoptotic
gene Bax.
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